Lactobacillus	O
gasseri	O
LG	O
-	O
G12	O
Restores	O
Gut	O
Microbiota	O
and	O
Intestinal	O
Health	O
in	O
Obesity	O
Mice	O
on	O
Ceftriaxone	O
Therapy	O
Lactobacillus	O
gasseriLG	O
-	O
G12	O
;	O
intestinal	O
health	O
;	O
ceftriaxone	O
;	O
gut	O
microbiota	O
;	O
obesity	O
Gut	O
microbiota	O
imbalance	O
is	O
associated	O
with	O
the	O
occurrence	O
of	O
metabolic	O
diseases	O
such	O
as	O
obesity	O
.	O
Thus	O
,	O
its	O
modulation	O
is	O
a	O
promising	O
strategy	O
to	O
restore	O
gut	O
microbiota	O
and	O
improve	O
intestinal	O
health	O
in	O
the	O
obese	O
.	O
This	O
paper	O
examines	O
the	O
role	O
of	O
probiotics	O
,	O
antimicrobials	O
,	O
and	O
diet	O
in	O
modulating	O
gut	O
microbiota	O
and	O
improving	O
intestinal	O
health	O
.	O
Accordingly	O
,	O
obesity	O
was	O
induced	O
in	O
C57BL	O
/	O
6J	O
mice	O
,	O
after	O
which	O
they	O
were	O
redistributed	O
and	O
fed	O
with	O
an	O
obesogenic	O
diet	O
(	O
intervention	O
A	O
)	O
or	O
standard	O
AIN	O
-	O
93	O
diet	O
(	O
intervention	O
B	O
)	O
.	O
Concomitantly	O
,	O
all	O
the	O
groups	O
underwent	O
a	O
treatment	O
phase	O
with	O
Lactobacillus	O
gasseri	O
LG	O
-	O
G12	O
,	O
ceftriaxone	O
,	O
or	O
ceftriaxone	O
followed	O
by	O
L	O
.	O
gasseri	O
LG	O
-	O
G12	O
.	O
At	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
the	O
following	O
analysis	O
was	O
conducted	O
:	O
metataxonomic	O
analysis	O
,	O
functional	O
profiling	O
of	O
gut	O
microbiota	O
,	O
intestinal	O
permeability	O
,	O
and	O
caecal	O
concentration	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
.	O
High	O
-	O
fat	O
diet	O
impaired	O
bacterial	O
diversity	O
/	O
richness	O
,	O
which	O
was	O
counteracted	O
in	O
association	O
with	O
L	O
.	O
gasseri	O
LG	O
-	O
G12	O
and	O
the	O
AIN	O
-	O
93	O
diet	O
.	O
Additionally	O
,	O
SCFA	O
-	O
producing	O
bacteria	O
were	O
negatively	O
correlated	O
with	O
high	O
intestinal	O
permeability	O
parameters	O
,	O
which	O
was	O
further	O
confirmed	O
via	O
functional	O
profile	O
prediction	O
of	O
the	O
gut	O
microbiota	O
.	O
A	O
novel	O
perspective	O
on	O
anti	O
-	O
obesity	O
probiotics	O
is	O
presented	O
by	O
these	O
findings	O
based	O
on	O
the	O
improvement	O
of	O
intestinal	O
health	O
irrespective	O
of	O
undergoing	O
antimicrobial	O
therapy	O
or	O
not	O
.	O
The	O
gut	O
is	O
home	O
to	O
approximately	O
70	O
%	O
of	O
the	O
microbiota	O
detected	O
in	O
humans	O
,	O
including	O
bacteria	O
,	O
fungi	O
,	O
viruses	O
,	O
and	O
protozoa	O
[	O
1	O
,	O
2	O
]	O
.	O
Modulation	O
of	O
gut	O
microbiota	O
composition	O
and	O
metabolic	O
functions	O
have	O
been	O
proposed	O
as	O
key	O
factors	O
that	O
control	O
obesity	O
development	O
[	O
2	O
,	O
3	O
]	O
.	O

External	O
modulators	O
of	O
gut	O
microbiota	O
include	O
probiotics	O
,	O
antimicrobials	O
,	O
and	O
diet	O
,	O
which	O
acts	O
with	O
speed	O
and	O
high	O
precision	O
in	O
order	O
to	O
impact	O
obesity	O
[	O
4	O
,	O
5	O
]	O
.	O
Probiotics	O
are	O
live	O
microorganisms	O
which	O
provide	O
health	O
benefits	O
to	O
host	O
when	O
consumed	O
in	O
sufficient	O
amounts	O
.	O
They	O
modulate	O
the	O
composition	O
and	O
metabolic	O
functions	O
of	O
the	O
gut	O
microbiota	O
,	O
and	O
contribute	O
to	O
immunological	O
functions	O
through	O
the	O
regulation	O
of	O
cytokines	O
,	O
promotion	O
of	O
oral	O
tolerance	O
to	O
food	O
antigens	O
,	O
and	O
improvement	O
of	O
intestinal	O
barrier	O
functions	O
[	O
5	O
]	O
.	O
In	O
this	O
context	O
,	O
several	O
probiotics	O
,	O
used	O
alone	O
or	O
as	O
synbiotic	O
mixtures	O
,	O
have	O
shown	O
antiobesity	O
effects	O
.	O
For	O
example	O
,	O
Lactobacillus	O
gasseri	O
has	O
beneficial	O
effects	O
on	O
weight	O
loss	O
and	O
body	O
fat	O
reduction	O
in	O
overweight	O
humans	O
and	O
animals	O
[	O
6	O
,	O
7	O
,	O
8	O
]	O
.	O
Alternatively	O
,	O
antimicrobials	O
can	O
contribute	O
to	O
the	O
loss	O
of	O
microbial	O
diversity	O
in	O
the	O
gut	O
over	O
time	O
,	O
impairing	O
metabolic	O
function	O
and	O
leading	O
to	O
impaired	O
metabolism	O
.	O
Therefore	O
,	O
they	O
potentially	O
reduce	O
the	O
colonization	O
resistance	O
against	O
invading	O
pathogens	O
,	O
resulting	O
in	O
dysbiosis	O
[	O
9	O
]	O
.	O
Antimicrobial	O
’	O
s	O
ability	O
to	O
alter	O
the	O
microbiota	O
of	O
the	O
gut	O
varies	O
based	O
on	O
diet	O
,	O
lifestyle	O
,	O
and	O
drug	O
spectrum	O
of	O
action	O
as	O
well	O
as	O
its	O
absorption	O
capacity	O
,	O
which	O
indicates	O
that	O
broader	O
spectrum	O
antimicrobials	O
such	O
as	O
ceftriaxone	O
result	O
in	O
intestinal	O
dysbiosis	O
more	O
frequently	O
[	O
10	O
,	O
11	O
]	O
.	O
Similarly	O
,	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
is	O
capable	O
of	O
promoting	O
intestinal	O
dysbiosis	O
,	O
thus	O
contributing	O
to	O
intestinal	O
barrier	O
dysfunction	O
,	O
immune	O
intolerance	O
to	O
food	O
antigens	O
,	O
activation	O
of	O
pro	O
-	O
inflammatory	O
routes	O
,	O
and	O
circadian	O
cycle	O
disruption	O
that	O
leads	O
to	O
weight	O
gain	O
,	O
abnormal	O
glucose	O
fluxes	O
,	O
and	O
inflammatory	O
response	O
[	O
12	O
]	O
.	O
In	O
contrast	O
,	O
balanced	O
and	O
diversified	O
diets	O
,	O
such	O
as	O
the	O
Mediterranean	O
standard	O
diet	O
,	O
rich	O
in	O
fruits	O
,	O
vegetables	O
,	O
whole	O
grains	O
,	O
and	O
seafood	O
,	O
promotes	O
a	O
diverse	O
gut	O
microbiota	O
,	O
thereby	O
stimulating	O
intestinal	O
barrier	O
function	O
and	O
immunity	O
[	O
13	O
]	O
.	O
Moreover	O
,	O
the	O
production	O
of	O
short	O
-	O
chain	O
fatty	O
acids	O
(	O
SCFAs	O
)	O
,	O
metabolites	O
of	O
gut	O
microbiota	O
,	O
and	O
intestinal	O
permeability	O
are	O
also	O
indicative	O
of	O
intestinal	O
and	O
systemic	O
health	O
[	O
14	O
,	O
15	O
]	O
.	O

SCFAs	O
have	O
numerous	O
beneficial	O
effects	O
on	O
the	O
host	O
from	O
increasing	O
mucus	O
and	O
tight	O
junction	O
expressions	O
in	O
the	O
intestinal	O
epithelium	O
to	O
metabolic	O
and	O
appetite	O
modulation	O
[	O
16	O
]	O
.	O
Intestinal	O
permeability	O
is	O
influenced	O
by	O
gut	O
microbiota	O
imbalance	O
and	O
is	O
one	O
of	O
the	O
main	O
factors	O
for	O
low	O
-	O
grade	O
inflammation	O
,	O
making	O
the	O
microbiome	O
a	O
central	O
player	O
as	O
regards	O
inflammatory	O
diseases	O
such	O
as	O
obesity	O
[	O
12	O
]	O
.	O
Given	O
the	O
above	O
,	O
there	O
is	O
a	O
need	O
for	O
insights	O
into	O
mechanisms	O
used	O
to	O
regulate	O
dysbiosis	O
in	O
obese	O
mice	O
.	O
Therefore	O
,	O
this	O
study	O
evaluated	O
how	O
a	O
potential	O
probiotic	O
Lactobacillus	O
gasseri	O
LG	O
-	O
G12	O
(	O
LG	O
-	O
G12	O
)	O
,	O
antimicrobial	O
ceftriaxone	O
,	O
and	O
diet	O
[	O
7	O
,	O
8	O
]	O
act	O
to	O
modulate	O
the	O
intestinal	O
microbiota	O
and	O
subsequently	O
impact	O
intestinal	O
health	O
parameters	O
.	O
Animal	O
Ethics	O
Committee	O
of	O
Universidade	O
Federal	O
de	O
Viçosa	O
approved	O
the	O
experiment	O
according	O
to	O
the	O
protocols	O
numbers	O
09	O
/	O
2017	O
and	O
33	O
/	O
2018	O
,	O
and	O
the	O
principles	O
established	O
by	O
the	O
National	O
Animal	B-methodology
Experimentation	I-methodology
Control	O
Council	O
[	O
17	O
]	O
.	O
An	O
experiment	O
was	O
conducted	O
using	O
72	O
male	O
C57BL	O
/	O
6J	O
mice	O
[	O
7	O
,	O
8	O
]	O
from	O
the	O
Central	O
Vivarium	O
of	O
the	O
Center	O
for	O
Biological	O
and	O
Health	O
Sciences	O
of	O
Universidade	O
Federal	O
de	O
Viçosa	O
(	O
UFV	O
)	O
.	O
The	O
mice	O
were	O
kept	O
in	O
collective	O
cages	O
(	O
two	O
animals	O
per	O
cage	O
)	O
and	O
were	O
submitted	O
to	O
a	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
and	O
an	O
average	O
temperature	O
of	O
22	O
±	O
2	O
°C	O
.	O
A	O
pair	O
-	O
feeding	O
scheme	O
was	O
used	O
to	O
administer	O
fructose	O
solution	O
and	O
a	O
diet	O
to	O
the	O
animals	O
throughout	O
the	O
experiment	O
.	O
All	O
animal	B-methodology
experiments	I-methodology
were	O
conducted	O
at	O
UFV	O
’	O
s	O
Experimental	O
Nutrition	O
Laboratory	O
.	O
At	O
5	O
weeks	O
,	O
the	O
animals	O
underwent	O
an	O
obesity	O
-	O
induced	O
protocol	O
that	O
lasted	O
3	O
months	O
(	O
induction	O
phase	O
)	O
.	O
During	O
this	O
initial	O
period	O
,	O
the	O
mice	O
were	O
fed	O
with	O
an	O
HFD	O
where	O
60	O
%	O
of	O
total	O
calories	O
were	O
derived	O
from	O
lipids	O
(	O
nutritional	O
composition	O
based	O
on	O
diet	O
D12492	O
of	O
the	O
Research	O
Diets	O
,	O
Inc	O
.	O
,	O
New	O
Brunswick	O
,	O
NJ	O
,	O
USA	O
)	O
[	O
18	O
]	O
,	O
and	O
a	O
10	O
%	O
fructose	O
solution	O
(	O
Synth®	O
,	O
Diadema	O
,	O
Brazil	O
)	O
instead	O
of	O
drinking	O
water	O
[	O
19	O
]	O
.	O

The	O
negative	O
control	B-methodology
group	I-methodology
(	O
G1	O
,	O
n	O
=	O
8	O
)	O
received	O
an	O
AIN	O
-	O
93	O
diet	O
,	O
with	O
10	O
%	O
of	O
total	O
calories	O
derived	O
from	O
lipids	O
[	O
20	O
]	O
and	O
water	O
from	O
the	O
induction	O
phase	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O
After	O
this	O
period	O
,	O
the	O
treatment	O
phase	O
began	O
and	O
the	O
mice	O
that	O
were	O
fed	O
with	O
an	O
HFD	O
were	O
randomly	B-methodology
divided	I-methodology
into	O
two	O
intervention	B-methodology
groups	I-methodology
(	O
A	O
and	O
B	O
)	O
with	O
a	O
subset	O
of	O
four	O
experimental	O
groups	O
each	O
(	O
Figure	O
1	O
)	O
:	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
(	O
G2	O
,	O
n	O
=	O
7	O
)	O
,	O
LG	O
-	O
G12	O
HFD	O
(	O
G3	O
,	O
n	O
=	O
7	O
)	O
,	O
cefriatoxane	O
HFD	O
(	O
G4	O
,	O
n	O
=	O
7	O
)	O
,	O
cefriatoxane	O
+	O
LG	O
-	O
G12	O
HFD	O
(	O
G5	O
,	O
n	O
=	O
7	O
)	O
,	O
standard	O
fat	O
diet	O
(	O
SFD	O
)	O
(	O
G6	O
,	O
n	O
=	O
8	O
)	O
,	O
LG	O
-	O
G12	O
SFD	O
(	O
G7	O
,	O
n	O
=	O
7	O
)	O
,	O
cefriatoxane	O
SFD	O
(	O
G8	O
,	O
n	O
=	O
7	O
)	O
,	O
and	O
cefriatoxane	O
+	O
LG	O
-	O
G12	O
SFD	O
(	O
G9	O
,	O
n	O
=	O
8	O
)	O
.	O
Intervention	O
A	O
groups	O
continually	O
received	O
an	O
obesogenic	O
diet	O
during	O
the	O
treatment	O
phase	O
.	O
The	O
obesogenic	O
diet	O
was	O
confirmed	O
by	O
Dias	O
et	O
al	O
.	O
[	O
7	O
]	O
.	O
In	O
contrast	O
,	O
intervention	O
B	O
groups	O
initiated	O
an	O
AIN	O
-	O
93	O
standard	O
diet	O
and	O
water	O
instead	O
of	O
fructose	O
solution	O
during	O
the	O
treatment	O
phase	O
.	O
A	O
gavage	B-methodology
treatment	O
was	O
administered	O
every	O
evening	O
at	O
the	O
same	O
time	O
.	O
The	O
antimicrobial	O
group	O
was	O
treated	O
with	O
500	O
mg	O
of	O
ceftriaxone	O
per	O
kg	O
of	O
body	O
mass	O
(	O
Triaxton	O
,	O
Blau	O
Farmacêutica	O
S	O
/	O
A®	O
,	O
Cotia	O
,	O
Brazil	O
)	O
[	O
21	O
]	O
.	O
The	O
potential	O
probiotic	O
group	O
received	O
109	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
of	O
LG	O
-	O
G12	O
(	O
Lemma	O
Supply	O
Solutions®	O
,	O
São	O
Paulo	O
,	O
Brazil	O
)	O
.	O
L	O
.	O
gasseri	O
LG	O
-	O
G12	O
was	O
lyophilized	O
and	O
diluted	O
into	O
200ul	O
of	O
water	O
.	O
Both	O
treatment	O
groups	O
received	O
500	O
mg	O
of	O
ceftriaxone	O
per	O
kg	O
of	O
body	O
weight	O
in	O
the	O
first	O
two	O
weeks	O
of	O
the	O
treatment	O
phase	O
and	O
,	O
in	O
the	O
following	O
two	O
weeks	O
,	O
109	O
CFU	O
of	O
L	O
.	O
gasseri	O
LG	O
-	O
G12	O
.	O

At	O
the	O
conclusion	O
of	O
the	O
treatment	O
phase	O
,	O
a	O
total	O
exsanguination	O
was	O
carried	O
out	O
after	O
the	O
animals	O
had	O
been	O
anesthetized	O
with	O
3	O
%	O
isoflurane	O
(	O
Cristália®	O
,	O
Belo	O
Horizonte	O
,	O
Brazil	O
)	O
and	O
euthanized	O
.	O
This	O
form	O
of	O
euthanasia	O
is	O
recommended	O
for	O
rodents	O
by	O
CONSEA	O
[	O
17	O
]	O
.	O
For	O
future	O
analyses	O
,	O
tissue	O
samples	O
were	O
collected	O
and	O
stored	O
.	O
More	O
information	O
about	O
the	O
experimental	B-methodology
design	I-methodology
is	O
available	O
at	O
Dias	O
et	O
al	O
.	O
[	O
7	O
]	O
.	O
As	O
previously	O
described	O
by	O
Dias	O
et	O
al	O
.	O
[	O
7	O
]	O
,	O
after	O
the	O
treatment	O
phase	O
,	O
a	O
lactulose	O
(	O
Daiichi	O
Sankyo®	O
,	O
Barueri	O
,	O
Brazil	O
)	O
and	O
mannitol	O
solution	O
(	O
Synth®	O
,	O
Diadema	O
,	O
Brazil	O
)	O
were	O
supplied	O
to	O
the	O
animals	O
.	O
Subsequently	O
,	O
the	O
24	O
h	O
urine	O
of	O
the	O
animals	O
was	O
collected	O
.	O
These	O
sugars	O
were	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
detector	O
model	O
RID	O
10A	O
,	O
Shimadzu®	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O
By	O
Siegfried	O
et	O
al	O
.	O
[	O
22	O
]	O
method	O
,	O
the	O
acetic	O
,	O
propionic	O
,	O
and	O
butyric	O
acids	O
,	O
of	O
the	O
cecal	O
content	O
,	O
were	O
determined	O
,	O
as	O
reported	O
by	O
Dias	O
et	O
al	O
.	O
[	O
7	O
]	O
,	O
and	O
analyzed	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
Ultimate	O
3000	O
,	O
Dionex	O
,	O
Thermo	O
Fisher	O
Scientific®	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
.	O
A	O
pool	O
of	O
stool	O
samples	O
was	O
made	O
as	O
described	O
by	O
Dias	O
et	O
al	O
.	O
[	O
7	O
]	O
.	O
This	O
methodology	O
was	O
adopted	O
because	O
the	O
animals	O
are	O
isogenic	O
and	O
live	O
in	O
a	O
controlled	B-methodology
environment	I-methodology
,	O
and	O
can	O
therefore	O
be	O
considered	O
biological	O
replicates	O
.	O
Metagenomic	O
DNA	O
was	O
extracted	O
from	O
200	O
mg	O
of	O
feces	O
using	O
the	O
method	O
adapted	O
from	O
Zhang	O
et	O
al	O
.	O
[	O
23	O
]	O
.	O
Afterward	O
,	O
the	O
quantity	O
of	O
the	O
extracted	O
DNA	O
was	O
evaluated	O
utilizing	O
Qubit	O
(	O
Invitrogen	O
,	O
Thermo	O
Fisher	O
,	O
USA	O
)	O
,	O
whereas	O
its	O
integrity	O
and	O
quality	O
were	O
verified	O
through	O
electrophoresis	O
in	O
1	O
.	O
8	O
%	O
agarose	O
gel	O
.	O

The	O
V3	O
and	O
V4	O
regions	O
of	O
16S	O
rRNA	O
genes	O
were	O
PCR	O
amplified	O
utilizing	O
specific	O
primers	O
(	O
Bakt	O
341F	O
and	O
Bakt	O
805R	O
)	O
and	O
sequenced	O
using	O
an	O
Illumina	O
MiSeq	O
desktop	O
sequencer	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
at	O
the	O
Macrogen	O
Company	O
(	O
Macrogen	O
Inc®	O
,	O
Seoul	O
,	O
South	O
Korea	O
)	O
.	O
Microbiota	O
data	O
were	O
processed	O
and	O
analyzed	O
with	O
QIIME2	O
(	O
version	O
2020	O
.	O
2	O
)	O
[	O
24	O
]	O
.	O
In	O
brief	O
,	O
raw	O
sequence	O
data	O
obtained	O
across	O
the	O
C57BL	O
/	O
6J	O
mice	O
stool	O
samples	O
from	O
group	O
G1	O
to	O
G9	O
were	O
imported	O
via	O
the	O
Casava1	O
.	O
8	O
paired	O
-	O
end	O
pipeline	O
followed	O
by	O
denoising	O
with	O
DADA2	O
[	O
25	O
]	O
(	O
via	O
q2	O
-	O
dada2	O
)	O
.	O
Subsequently	O
,	O
an	O
amplicon	O
sequence	O
variants	O
(	O
ASV	O
)	O
table	O
was	O
constructed	O
to	O
generate	O
a	O
phylogenetic	O
tree	O
by	O
using	O
the	O
align	O
-	O
to	O
-	O
tree	O
-	O
might	O
-	O
fast	O
tree	O
pipeline	O
from	O
the	O
q2	O
-	O
phylogeny	O
plugin	O
[	O
26	O
,	O
27	O
]	O
.	O
When	O
appropriate	O
,	O
samples	O
were	O
rarefied	O
to	O
a	O
sampling	O
depth	O
of	O
120	O
,	O
326	O
sequences	O
.	O
Taxonomy	O
was	O
assigned	O
to	O
the	O
16S	O
data	O
using	O
a	O
Naïve	O
Bayes	O
pre	O
-	O
trained	O
Greengenes	O
13	O
_	O
8	O
99	O
%	O
OTUs	O
classifier	O
[	O
28	O
]	O
.	O
For	O
the	O
functional	O
prediction	O
of	O
the	O
gut	O
microbiota	O
,	O
ASVs	O
(	O
read	O
sequences	O
and	O
read	O
counts	O
)	O
were	O
used	O
as	O
inputs	O
for	O
the	O
PICRUSt2	O
(	O
Phylogenetic	O
Investigation	O
of	O
Communities	O
by	O
Reconstruction	O
of	O
Unobserved	O
States	O
)	O
pipeline	O
[	O
29	O
]	O
.	O
In	O
brief	O
,	O
ASVs	O
were	O
inserted	O
and	O
aligned	O
into	O
a	O
reference	O
tree	O
composed	O
of	O
20	O
,	O
000	O
full	O
16S	O
rRNA	O
genes	O
from	O
bacterial	O
and	O
archaeal	O
genomes	O
using	O
,	O
respectively	O
,	O
the	O
HMMER	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hmmer	O
.	O
org	O
,	O
accessed	O
on	O
1	O
June	O
2021	O
)	O
and	O
EPA	O
-	O
ng	O
/	O
GAPPA	O
tools	O
[	O
30	O
,	O
31	O
]	O
.	O
Subsequently	O
,	O
the	O
castor	O
R	O
package	O
[	O
32	O
]	O
was	O
used	O
to	O
predict	O
the	O
missing	O
gene	O
families	O
(	O
Enzyme	O
Commission	O
numbers	O
)	O
for	O
each	O
ASV	O
,	O
as	O
well	O
as	O
their	O
respective	O
copy	O
number	O
of	O
16S	O
rRNA	O
gene	O
sequences	O
,	O
by	O
using	O
the	O
output	O
tree	O
generated	O
in	O
the	O
previous	O
step	O
.	O
Finally	O
,	O
MinPath	O
[	O
33	O
]	O
was	O
adopted	O
to	O
infer	O
MetaCyc	O
pathways	O
based	O
on	O
EC	O
number	O
abundances	O
.	O

Under	O
accession	O
numbers	O
PRJNA705760	O
and	O
PRJNA745938	O
,	O
the	O
raw	O
fastq	O
data	O
have	O
been	O
submitted	O
to	O
the	O
Sequence	O
Read	O
Archive	O
(	O
SRA	O
)	O
at	O
NCBI	O
.	O
The	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
was	O
performed	O
using	O
the	O
relative	O
abundance	O
of	O
the	O
most	O
abundant	O
genera	O
(	O
greater	O
than	O
0	O
.	O
1	O
%	O
in	O
at	O
least	O
one	O
sample	O
)	O
.	O
OTU	O
abundance	O
was	O
scaled	O
and	O
then	O
the	O
PCA	O
analysis	O
was	O
performed	O
using	O
the	O
prcomp	O
function	O
of	O
the	O
R	O
program	O
(	O
R	O
Core	O
Team	O
3	O
.	O
6	O
.	O
2	O
,	O
2019	O
)	O
.	O
Normalization	O
was	O
performed	O
to	O
assure	O
that	O
the	O
PCA	O
results	O
are	O
mathematically	O
independent	O
of	O
the	O
overlap	O
measure	O
.	O
The	O
factorial	O
analysis	O
for	O
OTU	O
information	O
aimed	O
at	O
obtaining	O
the	O
variables	O
which	O
contribute	O
to	O
the	O
highest	O
differentiation	O
across	O
the	O
treatment	O
groups	O
using	O
the	O
FactoMineR	O
R	O
package	O
[	O
34	O
]	O
.	O
Shapiro	O
-	O
Wilk	O
test	O
was	O
used	O
to	O
test	O
the	O
normality	O
of	O
the	O
variables	O
(	O
i	O
.	O
e	O
.	O
,	O
Shannon	O
,	O
Chao1	O
,	O
acetate	O
,	O
propionate	O
,	O
butyrate	O
,	O
total	O
SCFA	O
,	O
and	O
lactulose	O
/	O
mannitol	O
ratio	O
)	O
.	O
One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Tukey	O
’	O
s	O
post	O
hoc	O
test	O
was	O
adopted	O
for	O
parametric	O
data	O
,	O
and	O
Kruskal	O
Wallis	O
complemented	O
by	O
Dunn	O
’	O
s	O
multiple	O
-	O
comparison	O
test	O
was	O
used	O
for	O
non	O
-	O
parametric	O
data	O
.	O
The	O
results	O
were	O
expressed	O
as	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O
Differentially	O
abundant	O
taxa	O
after	O
the	O
treatment	O
phase	O
that	O
most	O
likely	O
explain	O
the	O
differences	O
among	O
the	O
groups	O
(	O
i	O
.	O
e	O
.	O
,	O
fecal	O
biomarkers	O
)	O
were	O
assessed	O
using	O
the	O
linear	O
discriminant	O
analysis	O
(	O
LDA	O
)	O
effect	O
size	O
(	O
LEfSe	O
)	O
[	O
35	O
]	O
tool	O
and	O
setting	O
an	O
alpha	O
value	O
of	O
0	O
.	O
05	O
and	O
Log	O
LDA	O
threshold	O
of	O
2	O
.	O
0	O
.	O
Beta	O
diversity	O
was	O
assessed	O
using	O
the	O
Unweighted	O
and	O
Weighted	O
UniFrac	O
metrics	O
to	O
evaluate	O
bacterial	O
community	O
dissimilarities	O
between	O
the	O
groups	O
.	O
Permutational	O
multivariate	O
analysis	O
of	O
variance	O
(	O
PERMANOVA	O
)	O
with	O
999	O
permutations	O
was	O
used	O
to	O
test	O
whether	O
distances	O
between	O
samples	O
within	O
a	O
certain	O
group	O
are	O
more	O
similar	O
to	O
each	O
other	O
or	O
not	O
.	O

Correlations	O
between	O
continuous	O
variables	O
were	O
determined	O
by	O
Pearson	O
’	O
s	O
(	O
parametric	O
data	O
)	O
or	O
Spearman	O
’	O
s	O
(	O
non	O
-	O
parametric	O
data	O
)	O
correlation	O
with	O
the	O
Paleontological	O
statistics	O
software	O
package	O
for	O
education	O
and	O
data	O
analysis	O
(	O
PAST	O
,	O
v4	O
.	O
06b	O
)	O
[	O
36	O
]	O
.	O
Lastly	O
,	O
the	O
Statistical	O
Analysis	O
of	O
Metagenomic	O
Profile	O
(	O
STAMP	O
)	O
software	O
[	O
37	O
]	O
was	O
used	O
to	O
explore	O
and	O
compare	O
the	O
metabolic	O
potential	O
of	O
the	O
predicted	O
microbial	O
communities	O
across	O
the	O
groups	O
.	O
Functional	O
profiling	O
was	O
built	O
based	O
on	O
the	O
MetaCyc	O
Metabolic	O
Pathway	O
Database	O
[	O
38	O
]	O
.	O
Welch	O
’	O
s	O
t	O
-	O
test	O
(	O
two	O
-	O
sided	O
)	O
was	O
adopted	O
as	O
a	O
statistical	O
hypothesis	O
test	O
.	O
For	O
both	O
analyses	O
,	O
a	O
p	O
-	O
value	O
less	O
than	O
0	O
.	O
05	O
was	O
considered	O
a	O
significant	O
difference	O
.	O
MDS	O
analysis	O
based	O
on	O
intestinal	O
microbiota	O
abundance	O
explains	O
around	O
38	O
.	O
9	O
%	O
of	O
the	O
variation	O
between	O
the	O
groups	O
(	O
G1	O
to	O
G9	O
)	O
(	O
Figure	O
2	O
)	O
.	O
In	O
intervention	O
“	O
B	O
”	O
(	O
groups	O
G1	O
,	O
G6	O
,	O
G7	O
,	O
G8	O
,	O
and	O
G9	O
)	O
there	O
is	O
microbial	O
homogeneity	O
between	O
G7	O
and	O
G9	O
.	O
Then	O
it	O
is	O
believed	O
that	O
LG	O
-	O
G12	O
acted	O
as	O
a	O
positive	O
modulator	O
of	O
the	O
intestinal	O
microbiota	O
(	O
Figure	O
2A	O
)	O
.	O
Moreover	O
,	O
distinct	O
bacterial	O
genera	O
contributed	O
differently	O
to	O
the	O
total	O
intestinal	O
microbial	O
load	O
across	O
the	O
different	O
experimental	O
groups	O
,	O
which	O
suggests	O
different	O
biological	O
and	O
/	O
or	O
metabolic	O
capabilities	O
(	O
Figure	O
2B	O
)	O
.	O
The	O
absence	O
of	O
differences	O
in	O
alpha	O
diversity	O
between	O
interventions	O
“	O
A	O
”	O
and	O
“	O
B	O
”	O
was	O
observed	O
(	O
Table	O
1	O
,	O
Figure	O
S1	O
)	O
.	O
However	O
,	O
in	O
the	O
groups	O
that	O
consumed	O
an	O
antimicrobial	O
and	O
high	O
-	O
fat	O
diet	O
(	O
G4	O
and	O
G5	O
)	O
,	O
a	O
tendency	O
towards	O
a	O
reduction	O
in	O
the	O
Shannon	O
and	O
Chao1	O
indices	O
could	O
be	O
observed	O
,	O
when	O
compared	O
to	O
those	O
who	O
received	O
ceftriaxone	O
and	O
a	O
standard	O
diet	O
(	O
G8	O
and	O
G9	O
)	O
.	O
This	O
result	O
shows	O
a	O
synergy	O
between	O
the	O
antibiotic	O
and	O
high	O
-	O
fat	O
diet	O
which	O
can	O
impair	O
bacterial	O
diversity	O
/	O
richness	O
.	O
As	O
previously	O
described	O
[	O
39	O
,	O
40	O
]	O
,	O
the	O
use	O
of	O
antibiotics	O
can	O
harm	O
the	O
intestinal	O
epithelium	O
,	O
as	O
well	O
as	O
favor	O
the	O
growth	O
of	O
specific	O
microbial	O
taxa	O
.	O

When	O
associated	O
with	O
high	O
-	O
calorie	O
diets	O
,	O
both	O
factors	O
can	O
contribute	O
negatively	O
to	O
the	O
development	O
of	O
the	O
gut	O
microbiota	O
[	O
40	O
,	O
41	O
]	O
,	O
which	O
justifies	O
our	O
findings	O
on	O
cefriatoxane	O
with	O
the	O
high	O
-	O
fat	O
diet	O
group	O
(	O
G4	O
)	O
.	O
Finally	O
,	O
switching	O
to	O
a	O
standard	O
diet	O
(	O
intervention	O
“	O
B	O
”	O
)	O
was	O
capable	O
of	O
increasing	O
intestinal	O
diversity	O
in	O
all	O
groups	O
,	O
which	O
justifies	O
the	O
lack	O
of	O
statistical	O
difference	O
.	O
Regarding	O
the	O
beta	O
-	O
diversity	O
analysis	O
,	O
there	O
was	O
no	O
difference	O
in	O
terms	O
of	O
gut	O
microbiota	O
dispersion	O
based	O
on	O
UniFrac	O
distance	O
metrics	O
(	O
weighted	O
UniFrac	O
:	O
F	O
-	O
value	O
=	O
0	O
.	O
77	O
;	O
p	O
=	O
0	O
.	O
49	O
;	O
unweighted	O
UniFrac	O
:	O
F	O
-	O
value	O
=	O
1	O
.	O
66	O
;	O
p	O
-	O
value	O
=	O
0	O
.	O
15	O
)	O
.	O
According	O
to	O
PERMANOVA	O
results	O
,	O
a	O
statistically	O
significant	O
difference	O
was	O
observed	O
regarding	O
community	O
dissimilarity	O
considering	O
both	O
UniFrac	O
indices	O
(	O
weighted	O
UniFrac	O
:	O
F	O
-	O
value	O
=	O
2	O
.	O
68	O
;	O
p	O
-	O
value	O
=	O
0	O
.	O
003	O
;	O
unweighted	O
UniFrac	O
:	O
F	O
-	O
value	O
=	O
1	O
.	O
75	O
;	O
p	O
-	O
value	O
=	O
0	O
.	O
002	O
)	O
.	O
Moreover	O
,	O
pairwise	O
comparisons	O
using	O
Qiime	O
beta	O
-	O
group	O
-	O
significance	O
command	O
revealed	O
that	O
the	O
gut	O
composition	O
of	O
the	O
group	O
that	O
received	O
ceftriaxone	O
and	O
a	O
high	O
-	O
fat	O
diet	O
(	O
G4	O
)	O
showed	O
the	O
greatest	O
distance	O
to	O
other	O
groups	O
,	O
especially	O
to	O
G1	O
(	O
Figure	O
S2	O
)	O
.	O
This	O
result	O
indicates	O
that	O
significant	O
differences	O
in	O
gut	O
microbial	O
composition	O
were	O
due	O
to	O
the	O
intervention	O
and	O
not	O
to	O
dispersion	O
effects	O
.	O
Taken	O
together	O
,	O
alpha	O
-	O
and	O
beta	O
-	O
diversity	O
indices	O
evidenced	O
that	O
a	O
synergy	O
between	O
antibiotics	O
and	O
a	O
high	O
-	O
fat	O
diet	O
can	O
impair	O
bacterial	O
community	O
structure	O
and	O
diversity	O
both	O
qualitatively	O
and	O
quantitatively	O
.	O
Overall	O
,	O
127	O
significantly	O
discriminative	O
features	O
(	O
LDA	O
>	O
2	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
identified	O
in	O
the	O
LEfSE	O
analysis	O
.	O
The	O
phyla	O
Proteobacteria	O
(	O
LDA	O
>	O
5	O
)	O
and	O
Spirochaetes	O
(	O
LDA	O
>	O
2	O
.	O
0	O
)	O
were	O
enriched	O
in	O
group	O
G3	O
,	O
whereas	O
the	O
phylum	O
Tenericutes	O
(	O
LDA	O
>	O
2	O
.	O
0	O
)	O
can	O
be	O
considered	O
a	O
biomarker	O
for	O
group	O
G4	O
(	O
Figure	O
3	O
)	O
.	O

The	O
consumption	O
of	O
a	O
processed	O
diet	O
,	O
commonly	O
rich	O
in	O
emulsifiers	O
and	O
artificial	O
sweeteners	O
,	O
can	O
explain	O
the	O
expansion	O
of	O
Proteobacteria	O
,	O
which	O
can	O
increase	O
intestinal	O
permeability	O
and	O
reduce	O
local	O
mucus	O
production	O
[	O
42	O
,	O
43	O
]	O
.	O
Regarding	O
the	O
phylum	O
Spirochaetes	O
,	O
although	O
its	O
identification	O
in	O
fecal	O
samples	O
has	O
not	O
been	O
associated	O
with	O
obesity	O
,	O
Jabbar	O
et	O
al	O
.	O
[	O
44	O
]	O
reported	O
the	O
association	O
between	O
Brachyspira	O
and	O
irritable	O
bowel	O
syndrome	O
.	O
Our	O
results	O
indicate	O
a	O
limited	O
impact	O
of	O
the	O
LG	O
-	O
G12	O
in	O
controlling	O
the	O
two	O
aforementioned	O
taxa	O
.	O
Since	O
a	O
single	O
strain	O
was	O
used	O
in	O
this	O
study	O
,	O
its	O
inclusion	O
in	O
a	O
multiple	O
strain	O
formulation	O
,	O
as	O
suggested	O
by	O
the	O
World	O
Gastroenterology	O
Organisation	O
[	O
5	O
]	O
,	O
might	O
represent	O
a	O
more	O
effective	O
strategy	O
in	O
limiting	O
the	O
growth	O
of	O
such	O
undesired	O
phyla	O
,	O
which	O
must	O
be	O
evaluated	O
in	O
further	O
studies	O
.	O
Nevertheless	O
,	O
Firmicutes	O
and	O
Bacteroidetes	O
have	O
not	O
been	O
identified	O
as	O
biomarkers	O
in	O
any	O
of	O
the	O
interventions	O
,	O
group	O
G4	O
showed	O
a	O
much	O
higher	O
F	O
/	O
B	O
ratio	O
(	O
Table	O
2	O
)	O
,	O
which	O
is	O
common	O
in	O
the	O
obese	O
population	O
[	O
42	O
]	O
.	O
This	O
means	O
that	O
the	O
combined	O
use	O
of	O
ceftriaxone	O
and	O
a	O
high	O
-	O
fat	O
diet	O
disrupts	O
the	O
intestinal	O
bacterial	O
balance	O
,	O
favoring	O
the	O
growth	O
of	O
a	O
few	O
phyla	O
at	O
the	O
expense	O
of	O
others	O
,	O
which	O
is	O
common	O
in	O
intestinal	O
dysbiosis	O
[	O
45	O
]	O
.	O
Interestingly	O
,	O
following	O
LG	O
-	O
G12	O
administration	O
,	O
the	O
F	O
/	O
B	O
ratio	O
decreased	O
in	O
the	O
cefriatoxane	O
+	O
LG	O
-	O
G12	O
A	O
group	O
(	O
G5	O
)	O
.	O
This	O
outcome	O
suggests	O
a	O
mechanism	O
of	O
counteraction	O
of	O
LG	O
-	O
G12	O
to	O
the	O
damage	O
caused	O
by	O
ceftriaxone	O
administration	O
favoring	O
the	O
restoration	O
of	O
intestinal	O
homeostasis	O
[	O
45	O
]	O
.	O
The	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
genera	O
ratio	O
was	O
also	O
evaluated	O
in	O
each	O
group	O
(	O
Table	O
2	O
)	O
.	O
As	O
expected	O
,	O
the	O
G4	O
group	O
presented	O
the	O
least	O
proportion	O
of	O
Gram	O
-	O
negative	O
among	O
all	O
groups	O
(	O
23	O
.	O
50	O
%	O
)	O
and	O
the	O
greatest	O
G	O
+	O
/	O
G−	O
ratio	O
(	O
3	O
.	O
24	O
)	O
,	O
indicating	O
the	O
selectivity	O
of	O
the	O
antimicrobial	O
ceftriaxone	O
against	O
this	O
specific	O
group	O
of	O
bacteria	O
.	O

Ceftriaxone	O
is	O
a	O
third	O
-	O
generation	O
cephalosporin	O
that	O
targets	O
most	O
Gram	O
-	O
negative	O
bacteria	O
inducing	O
changes	O
in	O
gut	O
microbiota	O
[	O
46	O
]	O
.	O
Our	O
results	O
also	O
reveal	O
that	O
the	O
intervention	O
with	O
LG	O
-	O
G12	O
alleviated	O
the	O
effects	O
of	O
the	O
synergism	O
between	O
the	O
antimicrobial	O
and	O
the	O
diet	O
offered	O
,	O
restoring	O
intestinal	O
Gram	O
-	O
negative	O
taxa	O
at	O
levels	O
similar	O
to	O
the	O
control	O
groups	O
.	O
Crovesy	O
et	O
al	O
.	O
[	O
6	O
]	O
,	O
in	O
a	O
systematic	B-methodology
review	I-methodology
of	I-methodology
randomized	I-methodology
controlled	I-methodology
clinical	I-methodology
trials	I-methodology
,	O
suggested	O
that	O
the	O
modulatory	O
effect	O
of	O
Lactobacillus	O
in	O
weight	O
loss	O
is	O
strain	O
-	O
dependent	O
and	O
can	O
require	O
its	O
association	O
with	O
calorie	O
restriction	O
,	O
phenolic	O
compounds	O
,	O
or	O
other	O
bacterial	O
strains	O
.	O
Amongst	O
the	O
biomarkers	O
identified	O
by	O
LEfSE	O
analysis	O
,	O
the	O
genera	O
Oscillospira	O
(	O
LDA	O
>	O
4	O
)	O
,	O
Sporosarcina	O
(	O
LDA	O
>	O
4	O
)	O
,	O
Allobaculum	O
(	O
LDA	O
>	O
3	O
)	O
,	O
Jeotgalicoccus	O
(	O
LDA	O
>	O
3	O
)	O
,	O
Bifidobacterium	O
(	O
LDA	O
>	O
3	O
)	O
,	O
and	O
Yaniella	O
(	O
LDA	O
>	O
3	O
)	O
were	O
assigned	O
as	O
biomarkers	O
for	O
group	O
G1	O
(	O
Figure	O
3	O
)	O
.	O
The	O
enrichment	O
of	O
the	O
genera	O
Bifidobacterium	O
is	O
in	O
agreement	O
with	O
the	O
literature	O
,	O
where	O
an	O
inverse	O
relationship	O
was	O
shown	O
between	O
this	O
genus	O
and	O
obesity	O
.	O
Bifidobacteria	O
deconjugate	O
bile	O
acids	O
,	O
decreasing	O
fat	O
absorption	O
[	O
47	O
]	O
.	O
The	O
higher	O
abundance	O
of	O
Oscillospira	O
in	O
the	O
gut	O
of	O
lean	O
subjects	O
has	O
been	O
addressed	O
in	O
several	O
studies	O
and	O
is	O
positively	O
associated	O
with	O
lower	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
both	O
children	O
and	O
adults	O
[	O
48	O
]	O
.	O
It	O
is	O
also	O
well	O
reported	O
that	O
a	O
high	O
-	O
fat	O
diet	O
can	O
significantly	O
reduce	O
the	O
intestinal	O
abundance	O
of	O
Allobaculum	O
,	O
a	O
relevant	O
SCFA	O
-	O
producing	O
bacteria	O
,	O
which	O
may	O
display	O
an	O
anti	O
-	O
obesogenic	O
role	O
by	O
reducing	O
intestinal	O
inflammation	O
and	O
improving	O
insulin	O
resistance	O
[	O
49	O
,	O
50	O
,	O
51	O
]	O
.	O
The	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
genera	O
Jeotgalicoccus	O
and	O
Sporosarcina	O
,	O
although	O
less	O
described	O
in	O
the	O
literature	O
,	O
are	O
associated	O
with	O
beneficial	O
outcomes	O
in	O
animal	B-methodology
models	I-methodology
fed	O
high	O
-	O
fat	O
diets	O
[	O
52	O
,	O
53	O
]	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
available	O
information	O
regarding	O
the	O
role	O
of	O
Yaniella	O
,	O
a	O
high	O
salt	O
-	O
tolerant	O
microorganism	O
,	O
in	O
healthy	O
or	O
obese	O
subjects	O
.	O
Overall	O
,	O
our	O
results	O
show	O
that	O
low	O
-	O
calorie	O
diets	O
are	O
beneficial	O
to	O
the	O
maintenance	O
of	O
taxa	O
that	O
are	O
negatively	O
associated	O
with	O
obesity	O
.	O
The	O
genera	O
Lactobacillus	O
(	O
LDA	O
>	O
4	O
)	O
,	O
Dehalobacterium	O
(	O
LDA	O
>	O
2	O
)	O
,	O
and	O
Erysipelotrichaceae	O
cc	O
_	O
115	O
(	O
LDA	O
>	O
3	O
)	O
were	O
identified	O
as	O
biomarkers	O
in	O
the	O
obese	O
control	B-methodology
group	I-methodology
(	O
G2	O
)	O
.	O
Although	O
most	O
lactobacilli	O
strains	O
can	O
have	O
beneficial	O
and	O
auxiliary	O
effects	O
on	O
weight	O
loss	O
in	O
overweight	O
adults	O
[	O
6	O
]	O
,	O
some	O
species	O
,	O
such	O
as	O
Limosilactobacillus	O
reuteri	O
have	O
been	O
associated	O
with	O
weight	O
gain	O
in	O
humans	O
and	O
animals	O
[	O
54	O
,	O
55	O
]	O
.	O
Regarding	O
the	O
genera	O
Dehalobacterium	O
and	O
Erysipelotrichaceae	O
cc	O
-	O
115	O
,	O
little	O
information	O
is	O
available	O
regarding	O
their	O
abundance	O
and	O
role	O
within	O
the	O
intestinal	O
community	O
of	O
obese	O
or	O
overweight	O
subjects	O
.	O
It	O
is	O
reported	O
that	O
the	O
genus	O
Dehalobacterium	O
comprehends	O
microorganisms	O
strictly	O
anaerobic	O
and	O
capable	O
of	O
degrading	O
dichloromethane	O
and	O
was	O
found	O
enriched	O
in	O
both	O
obese	O
and	O
non	O
-	O
obese	O
asthmatic	O
patients	O
[	O
56	O
]	O
,	O
whereas	O
Erysipelotrichaceae	O
cc	O
-	O
115	O
was	O
found	O
depleted	O
in	O
the	O
gut	O
microbiota	O
of	O
community	O
-	O
dwelling	O
physically	O
active	O
older	O
men	O
[	O
57	O
]	O
.	O
Six	O
different	O
genera	O
were	O
enriched	O
in	O
LG	O
-	O
G12	O
A	O
(	O
G3	O
)	O
after	O
the	O
end	O
of	O
the	O
experimental	O
period	O
:	O
Ruminococcus	O
(	O
LDA	O
>	O
4	O
)	O
,	O
Anaerotruncus	O
(	O
LDA	O
>	O
4	O
)	O
,	O
Bilophila	O
(	O
LDA	O
>	O
3	O
)	O
,	O
Desulfovibrio	O
(	O
LDA	O
>	O
3	O
)	O
,	O
Brachyspira	O
(	O
LDA	O
>	O
2	O
)	O
,	O
and	O
Coprococcus	O
(	O
LDA	O
>	O
2	O
)	O
.	O

We	O
observed	O
that	O
when	O
LG	O
-	O
G12	O
was	O
offered	O
to	O
animals	O
that	O
were	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
,	O
there	O
was	O
a	O
remarkable	O
enrichment	O
of	O
SCFA	O
-	O
producing	O
bacteria	O
such	O
as	O
Ruminococcus	O
,	O
Anaerotruncus	O
,	O
and	O
Coprococcus	O
which	O
are	O
commonly	O
found	O
in	O
the	O
microbiota	O
of	O
overweight	O
or	O
obese	O
patients	O
[	O
58	O
,	O
59	O
,	O
60	O
]	O
.	O
Intriguingly	O
,	O
we	O
also	O
detected	O
the	O
enrichment	O
of	O
taxa	O
involved	O
in	O
mucus	O
degradation	O
and	O
hydrogen	O
sulfide	O
production	O
such	O
as	O
Brachyspira	O
,	O
Bilophila	O
,	O
and	O
Desulfovibrio	O
,	O
which	O
may	O
indicate	O
a	O
limited	O
action	O
of	O
LG	O
-	O
G12	O
against	O
these	O
taxa	O
.	O
The	O
genera	O
Enterococcus	O
(	O
LDA	O
>	O
5	O
)	O
,	O
Salinispora	O
(	O
LDA	O
>	O
3	O
)	O
,	O
and	O
Akkermansia	O
(	O
LDA	O
>	O
4	O
)	O
were	O
identified	O
as	O
biomarkers	O
of	O
the	O
ceftriaxone	O
A	O
group	O
(	O
G4	O
)	O
,	O
whereas	O
only	O
Clostridium	O
(	O
LDA	O
>	O
4	O
)	O
was	O
significantly	O
enriched	O
in	O
the	O
ceftriaxone	O
+	O
LG	O
-	O
G12	O
A	O
group	O
(	O
G5	O
)	O
.	O
Interestingly	O
,	O
Akkermansia	O
,	O
which	O
is	O
a	O
Gram	O
-	O
negative	O
,	O
obligate	O
anaerobe	O
,	O
non	O
-	O
motile	O
,	O
non	O
-	O
spore	O
-	O
forming	O
bacterium	O
,	O
seems	O
to	O
be	O
resilient	O
to	O
the	O
adverse	O
effects	O
of	O
the	O
antimicrobial	O
ceftriaxone	O
.	O
This	O
genus	O
has	O
attracted	O
great	O
interest	O
due	O
to	O
its	O
capability	O
to	O
enhance	O
mucus	O
formation	O
,	O
activate	O
the	O
innate	O
immune	O
system	O
,	O
and	O
promote	O
intestinal	O
homeostasis	O
[	O
61	O
]	O
.	O
As	O
reported	O
by	O
Vesić	O
&	O
Kristich	O
[	O
62	O
]	O
,	O
the	O
genus	O
Enterococcus	O
is	O
intrinsically	O
resistant	O
to	O
cephalosporins	O
,	O
antibiotics	O
that	O
act	O
on	O
cell	O
wall	O
biosynthesis	O
,	O
which	O
may	O
explain	O
its	O
identification	O
as	O
a	O
biomarker	O
of	O
this	O
group	O
.	O
Additionally	O
,	O
Mishra	O
&	O
Ghosh	O
[	O
63	O
]	O
reports	O
that	O
the	O
E	O
.	O
faecalis	O
AG5	O
strain	O
mitigates	O
HFD	O
-	O
induced	O
obesity	O
through	O
several	O
mechanisms	O
such	O
as	O
activation	O
of	O
adipocyte	O
apoptosis	O
and	O
the	O
improvement	O
of	O
glucose	O
,	O
insulin	O
,	O
and	O
leptin	O
sensitivity	O
.	O

The	O
genus	O
Corynebacterium	O
(	O
LDA	O
>	O
3	O
)	O
was	O
identified	O
as	O
a	O
biomarker	O
of	O
group	O
G1	O
,	O
while	O
the	O
genera	O
Blautia	O
(	O
LDA	O
>	O
3	O
)	O
,	O
Clostridium	O
(	O
LDA	O
>	O
4	O
)	O
,	O
and	O
Akkermansia	O
(	O
LDA	O
>	O
5	O
)	O
appear	O
enriched	O
in	O
the	O
control	B-methodology
group	I-methodology
G6	O
(	O
AIN	O
-	O
93	O
intake	O
during	O
the	O
treatment	O
phase	O
)	O
.	O
The	O
enrichment	O
of	O
the	O
SCFA	O
-	O
producing	O
bacteria	O
Akkermansia	O
,	O
Blautia	O
,	O
and	O
Clostridium	O
may	O
contribute	O
to	O
restoring	O
intestinal	O
integrity	O
and	O
the	O
development	O
of	O
intestinal	O
homeostasis	O
.	O
During	O
calorie	O
-	O
restricted	O
diet	O
therapy	O
for	O
overweight	O
or	O
obese	O
individuals	O
,	O
insulin	O
resistance	O
improves	O
and	O
is	O
correlated	O
with	O
an	O
increased	O
abundance	O
of	O
Akkermansia	O
in	O
the	O
gut	O
[	O
61	O
]	O
.	O
Finally	O
,	O
an	O
enrichment	O
of	O
the	O
Bifidobacterium	O
genus	O
(	O
LDA	O
>	O
4	O
)	O
was	O
observed	O
following	O
LG	O
-	O
G12	O
with	O
a	O
standard	O
diet	O
in	O
the	O
treatment	O
phase	O
(	O
G7	O
)	O
.	O
This	O
result	O
indicates	O
a	O
synergism	O
between	O
LG	O
-	O
G12	O
and	O
endogenous	O
bifidobacteria	O
,	O
which	O
might	O
be	O
strain	O
-	O
specific	O
.	O
Following	O
probiotic	O
intervention	O
with	O
Latilactobacillus	O
curvatus	O
and	O
Lactiplantibacillus	O
plantarum	O
,	O
Park	O
et	O
al	O
.	O
[	O
64	O
]	O
observed	O
enrichment	O
of	O
Bifidobacterium	O
pseudolongum	O
species	O
in	O
HFD	O
-	O
probiotic	O
mice	O
when	O
compared	O
to	O
the	O
HFD	O
-	O
placebo	B-methodology
group	I-methodology
.	O
Differentially	O
abundant	O
genera	O
were	O
not	O
identified	O
in	O
the	O
ceftriaxone	O
(	O
G8	O
)	O
and	O
ceftriaxone	O
+	O
LG	O
-	O
G12	O
groups	O
(	O
G9	O
)	O
.	O
The	O
genera	O
Enterococcus	O
(	O
r	O
=	O
−0	O
.	O
59	O
,	O
p	O
=	O
6	O
.	O
27	O
×	O
10−3	O
)	O
and	O
Bifidobacterium	O
(	O
r	O
=	O
−0	O
.	O
54	O
,	O
p	O
=	O
1	O
.	O
32	O
×	O
10−2	O
)	O
were	O
negatively	O
correlated	O
with	O
high	O
Lactulose	O
/	O
Mannitol	O
(	O
L	O
/	O
M	O
)	O
ratio	O
(	O
Table	O
3	O
)	O
,	O
in	O
LG	O
-	O
G12	O
treated	O
groups	O
(	O
G3	O
and	O
G7	O
)	O
(	O
Figure	O
4A	O
)	O
.	O
Species	O
of	O
the	O
genus	O
Enterococcus	O
can	O
interact	O
with	O
mucosal	O
immune	O
cells	O
,	O
thus	O
activating	O
intestinal	O
immune	O
response	O
[	O
64	O
]	O
.	O

Wu	O
et	O
al	O
.	O
[	O
65	O
]	O
report	O
that	O
the	O
probiotic	O
E	O
.	O
faecium	O
NCIMB	O
11181	O
can	O
ameliorate	O
necrotic	O
enteritis	O
by	O
improving	O
intestinal	O
mucosal	O
barrier	O
function	O
and	O
modulating	O
gut	O
microbiota	O
.	O
Bifidobacterium	O
,	O
which	O
is	O
indicative	O
of	O
microbial	O
diversity	O
[	O
66	O
]	O
,	O
can	O
protect	O
against	O
obesity	O
and	O
diabetes	O
,	O
as	O
well	O
as	O
improve	O
intestinal	O
integrity	O
and	O
control	O
metabolic	O
endotoxemia	O
,	O
important	O
parameters	O
for	O
the	O
assessment	O
of	O
intestinal	O
balance	O
and	O
health	O
[	O
41	O
,	O
67	O
]	O
.	O
In	O
terms	O
of	O
SCFA	O
production	O
(	O
Figure	O
4B	O
,	O
Table	O
3	O
)	O
,	O
the	O
genera	O
Enterococcus	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
p	O
=	O
3	O
.	O
12	O
×	O
10−2	O
)	O
,	O
Allobaculum	O
(	O
r	O
=	O
0	O
.	O
76	O
,	O
p	O
=	O
8	O
.	O
96	O
×	O
10−5	O
)	O
,	O
Sporosarcina	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
p	O
=	O
4	O
.	O
73	O
×	O
10−6	O
)	O
,	O
Jeotgalicoccus	O
(	O
r	O
=	O
0	O
.	O
87	O
,	O
p	O
=	O
7	O
.	O
67	O
×	O
10−7	O
)	O
,	O
Staphylococcus	O
(	O
r	O
=	O
0	O
.	O
91	O
,	O
p	O
=	O
2	O
.	O
50	O
×	O
10−8	O
)	O
,	O
Bifidobacterium	O
(	O
r	O
=	O
0	O
.	O
60	O
,	O
p	O
=	O
4	O
.	O
79	O
×	O
10−3	O
)	O
,	O
Blautia	O
(	O
r	O
=	O
0	O
.	O
59	O
,	O
p	O
=	O
6	O
.	O
11	O
×	O
10−3	O
)	O
were	O
positively	O
correlated	O
with	O
the	O
total	O
amount	O
of	O
SCFA	O
,	O
whereas	O
Prevotella	O
(	O
r	O
=	O
0	O
.	O
50	O
,	O
p	O
=	O
2	O
.	O
33	O
×	O
10−2	O
)	O
was	O
only	O
positively	O
correlated	O
with	O
the	O
production	O
of	O
butyrate	O
.	O
Kong	O
et	O
al	O
.	O
[	O
41	O
]	O
reported	O
that	O
the	O
consumption	O
of	O
high	O
-	O
fat	O
and	O
high	O
-	O
sucrose	O
diets	O
reduces	O
the	O
abundance	O
of	O
Prevotella	O
and	O
,	O
consequently	O
,	O
butyrate	O
levels	O
.	O
In	O
addition	O
,	O
the	O
probiotic	O
administration	O
(	O
Lactobacillus	O
acidophilus	O
,	O
Bifidobacterium	O
longum	O
,	O
and	O
Enterococcus	O
faecalis	O
)	O
can	O
restore	O
the	O
intestinal	O
microbiota	O
,	O
increasing	O
microorganisms	O
such	O
as	O
Lactobacillus	O
,	O
Bifidobacterium	O
,	O
and	O
Akkermansia	O
.	O
Based	O
on	O
our	O
results	O
,	O
we	O
believe	O
that	O
LG	O
-	O
G12	O
positively	O
modulated	O
SCFA	O
-	O
producing	O
bacteria	O
such	O
as	O
Allobaculum	O
,	O
Bifidobacterium	O
,	O
and	O
Prevotella	O
.	O

Overall	O
,	O
the	O
bacterial	O
genera	O
that	O
negatively	O
correlated	O
with	O
the	O
L	O
/	O
M	O
ratio	O
were	O
positively	O
correlated	O
with	O
the	O
production	O
of	O
SCFA	O
,	O
indicating	O
a	O
relevant	O
role	O
of	O
such	O
organic	O
acids	O
with	O
the	O
integrity	O
of	O
the	O
intestinal	O
barrier	O
,	O
which	O
is	O
in	O
line	O
with	O
previous	O
studies	O
[	O
41	O
,	O
68	O
,	O
69	O
]	O
.	O
The	O
correlation	O
analysis	O
performed	O
considering	O
groups	O
G4	O
,	O
and	O
G8	O
(	O
Figure	O
S3A	O
,	O
Table	O
3	O
)	O
revealed	O
that	O
Staphylococcus	O
(	O
r	O
=	O
−0	O
.	O
81	O
,	O
p	O
=	O
7	O
.	O
49	O
×	O
10−4	O
)	O
was	O
negatively	O
correlated	O
with	O
lactulose	O
,	O
whereas	O
Clostridium	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
p	O
=	O
3	O
.	O
79	O
×	O
10−2	O
)	O
was	O
positively	O
correlated	O
with	O
L	O
/	O
M	O
ratio	O
.	O
Zeng	O
et	O
al	O
.	O
[	O
70	O
]	O
reported	O
that	O
lactulose	O
inhibited	O
the	O
effect	O
of	O
Staphylococcus	O
aureus	O
due	O
to	O
the	O
production	O
of	O
sialyllactulose	O
,	O
an	O
antimicrobial	O
enzyme	O
capable	O
to	O
cause	O
damage	O
to	O
the	O
S	O
.	O
aureus	O
cell	O
membrane	O
,	O
which	O
can	O
be	O
good	O
for	O
intestinal	O
health	O
.	O
The	O
positive	O
correlation	O
between	O
Clostridium	O
and	O
a	O
high	O
L	O
/	O
M	O
ratio	O
is	O
not	O
news	O
as	O
some	O
species	O
such	O
as	O
Clostridium	O
difficile	O
can	O
secrete	O
toxins	O
with	O
cytotoxic	O
effects	O
on	O
the	O
intestinal	O
epithelium	O
[	O
71	O
]	O
.	O
In	O
terms	O
of	O
SCFA	O
(	O
Figure	O
S3B	O
,	O
Table	O
3	O
)	O
,	O
the	O
genera	O
Allobaculum	O
(	O
r	O
=	O
0	O
.	O
67	O
,	O
p	O
=	O
1	O
.	O
59	O
×	O
10−3	O
)	O
and	O
Bifidobacterium	O
(	O
r	O
=	O
0	O
.	O
54	O
,	O
p	O
=	O
1	O
.	O
72	O
×	O
10−2	O
)	O
,	O
were	O
positively	O
correlated	O
with	O
total	O
SCFA	O
production	O
,	O
whereas	O
only	O
the	O
genus	O
Stenotrophomonas	O
(	O
r	O
=	O
−0	O
.	O
48	O
,	O
p	O
=	O
3	O
.	O
76	O
×	O
10−2	O
)	O
showed	O
a	O
negative	O
correlation	O
.	O
Even	O
following	O
antimicrobial	O
treatment	O
,	O
the	O
genera	O
Allobaculum	O
and	O
Bifidobacterium	O
were	O
negatively	O
correlated	O
with	O
the	O
L	O
/	O
M	O
ratio	O
and	O
positively	O
correlated	O
with	O
the	O
production	O
of	O
SCFA	O
,	O
which	O
indicate	O
that	O
these	O
genera	O
may	O
act	O
in	O
the	O
maintenance	O
of	O
intestinal	O
integrity	O
and	O
homeostasis	O
as	O
previously	O
described	O
by	O
Kong	O
et	O
al	O
.	O
[	O
41	O
]	O
.	O

Regarding	O
the	O
genus	O
Stenotrophomonas	O
,	O
some	O
species	O
belonging	O
to	O
this	O
genus	O
,	O
such	O
as	O
Stenotrophomonas	O
maltophilia	O
,	O
are	O
considered	O
pathogenic	O
bacteria	O
[	O
72	O
]	O
and	O
highly	O
resistant	O
to	O
antibiotics	O
[	O
73	O
]	O
,	O
which	O
may	O
justify	O
its	O
presence	O
among	O
the	O
ceftriaxone	O
-	O
treated	O
groups	O
.	O
Correlation	O
analyses	O
encompassing	O
groups	O
G5	O
and	O
G9	O
(	O
Figure	O
S4A	O
)	O
revealed	O
that	O
the	O
genus	O
Desulfovibrio	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
p	O
=	O
3	O
.	O
29	O
×	O
10−2	O
)	O
was	O
positively	O
correlated	O
with	O
L	O
/	O
M	O
ratio	O
and	O
,	O
consequently	O
,	O
loss	O
of	O
intestinal	O
integrity	O
.	O
Desulfovibrio	O
members	O
are	O
frequently	O
elevated	O
in	O
intestinal	O
dysbiosis	O
,	O
causing	O
intestinal	O
permeability	O
and	O
inflammation	O
[	O
74	O
]	O
,	O
which	O
is	O
consistent	O
with	O
our	O
findings	O
.	O
Concerning	O
SCFAs	O
(	O
Figure	O
S4B	O
)	O
,	O
the	O
genera	O
Prevotella	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
p	O
=	O
2	O
.	O
98	O
×	O
10−2	O
)	O
and	O
Faecalibacterium	O
(	O
r	O
=	O
0	O
.	O
50	O
,	O
p	O
=	O
2	O
.	O
44	O
×	O
10−2	O
)	O
were	O
positively	O
correlated	O
with	O
their	O
total	O
amount	O
(	O
represented	O
here	O
by	O
the	O
sum	O
of	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
)	O
,	O
whereas	O
some	O
genera	O
were	O
positively	O
correlated	O
with	O
only	O
certain	O
compounds	O
,	O
but	O
not	O
with	O
total	O
production	O
,	O
as	O
follows	O
:	O
Allobaculum	O
(	O
Acetic	O
:	O
r	O
=	O
0	O
.	O
88	O
,	O
p	O
=	O
2	O
.	O
95	O
×	O
10−3	O
;	O
Propionic	O
,	O
r	O
=	O
0	O
.	O
73	O
,	O
p	O
=	O
2	O
.	O
70	O
×	O
10−4	O
;	O
Butyric	O
,	O
r	O
=	O
0	O
.	O
64	O
,	O
p	O
=	O
2	O
.	O
62	O
×	O
10−3	O
)	O
and	O
Bifidobacterium	O
(	O
Acetic	O
,	O
r	O
=	O
0	O
.	O
81	O
,	O
p	O
=	O
1	O
.	O
71	O
×	O
10−2	O
;	O
Propionic	O
,	O
r	O
=	O
0	O
.	O
67	O
,	O
p	O
=	O
1	O
.	O
11	O
×	O
10−3	O
;	O
Butyric	O
,	O
r	O
=	O
0	O
.	O
74	O
,	O
p	O
=	O
1	O
.	O
87	O
×	O
10−4	O
)	O
.	O
Acetate	O
and	O
lactate	O
are	O
among	O
the	O
SCFAs	O
produced	O
by	O
Bifidobacterium	O
[	O
75	O
]	O
,	O
whereas	O
butyrate	O
production	O
in	O
particular	O
is	O
more	O
related	O
to	O
prebiotics	O
,	O
as	O
discussed	O
previously	O
[	O
68	O
]	O
.	O
The	O
identification	O
of	O
Faecalibacterium	O
and	O
Allobaculum	O
,	O
both	O
genera	O
described	O
as	O
producers	O
of	O
SCFA	O
[	O
41	O
,	O
69	O
]	O
.	O

This	O
association	O
may	O
also	O
improve	O
intestinal	O
health	O
by	O
promoting	O
SCFA	O
-	O
producing	O
genera	O
and	O
,	O
consequently	O
,	O
enhancing	O
the	O
gut	O
microbiota	O
.	O
During	O
the	O
different	O
interventions	O
evaluated	O
in	O
the	O
current	O
study	O
,	O
we	O
aimed	O
to	O
identify	O
whether	O
microbial	O
metabolic	O
pathways	O
were	O
enriched	O
in	O
the	O
gut	O
microbiota	O
,	O
which	O
could	O
be	O
associated	O
with	O
the	O
effects	O
of	O
a	O
high	O
-	O
fat	O
diet	O
or	O
not	O
.	O
In	O
addition	O
,	O
we	O
focused	O
on	O
identifying	O
metabolic	O
pathways	O
related	O
to	O
SCFA	O
production	O
that	O
can	O
directly	O
impact	O
intestinal	O
health	O
.	O
Taking	O
into	O
account	O
the	O
comparison	O
between	O
groups	O
G7	O
and	O
G3	O
,	O
58	O
functional	O
pathways	O
differed	O
significantly	O
between	O
the	O
groups	O
(	O
Table	O
S1	O
)	O
,	O
and	O
the	O
great	O
majority	O
(	O
approximately	O
69	O
.	O
0	O
%	O
)	O
were	O
enriched	O
in	O
group	O
G7	O
.	O
Regarding	O
the	O
MetaCyc	O
pathways	O
associated	O
with	O
SCFA	O
production	O
,	O
six	O
metabolic	O
pathways	O
were	O
identified	O
(	O
Figure	O
5	O
)	O
,	O
and	O
four	O
of	O
them	O
were	O
present	O
in	O
group	O
G7	O
(	O
Bifidobacterium	O
shunt	O
,	O
heterolactic	O
fermentation	O
,	O
hexitol	O
fermentation	O
to	O
lactate	O
,	O
formate	O
,	O
ethanol	O
,	O
and	O
acetate	O
)	O
.	O
The	O
enrichment	O
of	O
Bifidobacterium	O
shunt	O
,	O
which	O
is	O
a	O
classic	O
pathway	O
of	O
carbohydrate	O
metabolisms	O
such	O
as	O
fructose	O
and	O
glucose	O
,	O
can	O
generate	O
compounds	O
serving	O
as	O
an	O
energy	O
source	O
for	O
intestinal	O
epithelial	O
cells	O
[	O
68	O
,	O
75	O
]	O
,	O
which	O
explains	O
the	O
greater	O
intestinal	O
integrity	O
noticed	O
in	O
this	O
group	O
.	O
Only	O
the	O
acetyl	O
-	O
Coa	O
fermentation	O
to	O
butanoate	O
II	O
and	O
L	O
-	O
lysine	O
fermentation	O
to	O
acetate	O
and	O
butanoate	O
pathways	O
were	O
enriched	O
in	O
the	O
G3	O
group	O
.	O
In	O
the	O
groups	O
that	O
underwent	O
ceftriaxone	O
treatment	O
followed	O
by	O
LG	O
-	O
G12	O
(	O
groups	O
G5	O
and	O
G9	O
)	O
,	O
only	O
14	O
functional	O
pathways	O
differed	O
significantly	O
between	O
both	O
groups	O
(	O
Table	O
S2	O
)	O
with	O
approximately	O
64	O
.	O
0	O
%	O
of	O
the	O
features	O
enriched	O
in	O
the	O
G9	O
group	O
.	O
The	O
enrichment	O
of	O
the	O
super	O
pathway	O
of	O
D	O
-	O
glucarate	O
and	O
D	O
-	O
galactarate	O
degradation	O
in	O
group	O
G5	O
also	O
demonstrates	O
the	O
use	O
of	O
alternative	O
carbon	O
sources	O
for	O
growth	O
.	O
The	O
use	O
of	O
dicarboxylic	O
acid	O
sugars	O
as	O
growth	O
substrate	O
occurs	O
in	O
many	O
different	O
bacteria	O
but	O
is	O
especially	O
found	O
in	O
Gram	O
-	O
negative	O
bacteria	O
such	O
as	O
members	O
of	O
the	O
Enterobacteriaceae	O
,	O
Moraxellaceae	O
,	O
and	O
Pseudomonadaceae	O
families	O
[	O
76	O
]	O
.	O

Metabolic	O
pathways	O
,	O
Bifidobacterium	O
shunt	O
,	O
and	O
heterolactic	O
fermentation	O
,	O
associated	O
with	O
SCFA	O
production	O
were	O
enriched	O
only	O
in	O
group	O
G9	O
(	O
Figure	O
S5	O
)	O
.	O
Similarly	O
,	O
in	O
the	O
G9	O
group	O
,	O
we	O
also	O
observed	O
the	O
enrichment	O
of	O
the	O
Bifidobacterium	O
shunt	O
and	O
heterolactic	O
fermentation	O
pathways	O
,	O
both	O
associated	O
with	O
carbohydrate	O
metabolism	O
[	O
77	O
]	O
,	O
which	O
evidence	O
an	O
important	O
role	O
of	O
low	O
-	O
calorie	O
diets	O
in	O
the	O
enrichment	O
of	O
these	O
functions	O
.	O
Interestingly	O
,	O
the	O
super	O
pathway	O
of	O
D	O
-	O
glucarate	O
and	O
D	O
-	O
galactarate	O
degradation	O
and	O
the	O
pathway	O
of	O
purine	O
nucleotide	O
degradation	O
II	O
(	O
aerobic	O
)	O
were	O
enriched	O
in	O
the	O
G5	O
group	O
.	O
This	O
indicates	O
that	O
this	O
group	O
of	O
microbes	O
is	O
using	O
alternative	O
carbon	O
sources	O
.	O
Finally	O
,	O
12	O
functional	O
pathways	O
differed	O
significantly	O
between	O
groups	O
G4	O
and	O
G8	O
(	O
ceftriaxone	O
administration	O
only	O
)	O
(	O
Table	O
S3	O
)	O
,	O
with	O
the	O
vast	O
majority	O
of	O
pathways	O
(	O
approximately	O
66	O
.	O
0	O
%	O
)	O
being	O
enriched	O
in	O
the	O
G4	O
group	O
.	O
The	O
main	O
metabolic	O
pathways	O
enriched	O
in	O
the	O
G4	O
group	O
were	O
associated	O
with	O
menaquinol	O
biosynthesis	O
and	O
de	O
novo	O
nucleotide	O
biosynthesis	O
.	O
The	O
enrichment	O
of	O
menaquinol	O
biosynthesis	O
might	O
be	O
related	O
to	O
the	O
energy	O
processes	O
of	O
bacteria	O
since	O
menaquinones	O
are	O
relevant	O
growth	O
factors	O
for	O
gut	O
microbiota	O
[	O
78	O
,	O
79	O
]	O
Traditionally	O
,	O
the	O
gut	O
microbiota	O
is	O
an	O
important	O
source	O
of	O
purines	O
,	O
which	O
are	O
used	O
in	O
different	O
functions	O
related	O
to	O
the	O
intestinal	O
barrier	O
and	O
innate	O
immunity	O
,	O
being	O
necessary	O
for	O
intestinal	O
protection	O
and	O
health	O
[	O
80	O
]	O
.	O
Since	O
dysbiosis	O
was	O
observed	O
in	O
group	O
G4	O
,	O
it	O
is	O
believed	O
that	O
the	O
enrichment	O
of	O
nucleotide	O
biosynthesis	O
pathways	O
confirms	O
an	O
expansion	O
of	O
specific	O
microbial	O
taxa	O
in	O
this	O
group	O
.	O
Consumption	O
of	O
a	O
high	O
-	O
fat	O
diet	O
associated	O
with	O
ceftriaxone	O
was	O
able	O
to	O
reduce	O
microbial	O
diversity	O
.	O
It	O
was	O
observed	O
that	O
LG	O
-	O
G12	O
had	O
the	O
best	O
effects	O
when	O
it	O
was	O
combined	O
with	O
a	O
low	O
-	O
calorie	O
diet	O
in	O
restoring	O
gut	O
homeostasis	O
.	O
Higher	O
caecal	O
SCFA	O
contributed	O
to	O
increased	O
intestinal	O
integrity	O
.	O

Also	O
,	O
the	O
genera	O
that	O
presented	O
a	O
negative	O
correlation	O
with	O
a	O
high	O
L	O
/	O
M	O
ratio	O
were	O
similar	O
to	O
those	O
that	O
had	O
a	O
positive	O
correlation	O
with	O
total	O
SCFA	O
production	O
.	O
This	O
trend	O
was	O
further	O
confirmed	O
by	O
metagenomic	O
predictions	O
of	O
the	O
gut	O
microbiota	O
.	O
LG	O
-	O
G12	O
is	O
presented	O
in	O
this	O
study	O
as	O
a	O
novel	O
adjuvant	O
treatment	O
for	O
overweight	O
or	O
obese	O
individuals	O
through	O
gut	O
microbiota	O
modulation	O
and	O
improvement	O
of	O
intestinal	O
health	O
in	O
models	O
undergoing	O
antimicrobial	O
therapy	O
or	O
not	O
.	O
This	O
research	O
was	O
funded	O
by	O
the	O
Coordenação	O
de	O
Aperfeiçoamento	O
de	O
Pessoal	O
de	O
Nível	O
Superior	O
(	O
CAPES	O
)	O
(	O
Scholarship	O
number	O
88887	O
.	O
500342	O
/	O
2020	O
-	O
00	O
)	O
,	O
Conselho	O
Nacional	O
de	O
Desenvolvimento	O
Científico	O
e	O
Tecnológico	O
(	O
CNPq	O
)	O
(	O
Process	O
number	O
303511	O
/	O
2019	O
-	O
2	O
)	O
and	O
Fundação	O
de	O
Amparo	O
à	O
Pesquisa	O
de	O
Minas	O
Gerais	O
(	O
FAPEMIG	O
)	O
(	O
Edital	O
01	O
-	O
2017	O
,	O
APQ	O
-	O
00539	O
-	O
17	O
)	O
.	O
Disclaimer	O
/	O
Publisher	O
’	O
s	O
Note	O
:	O
The	O
statements	O
,	O
opinions	O
and	O
data	O
contained	O
in	O
all	O
publications	O
are	O
solely	O
those	O
of	O
the	O
individual	O
author	O
(	O
s	O
)	O
and	O
contributor	O
(	O
s	O
)	O
and	O
not	O
of	O
MDPI	O
and	O
/	O
or	O
the	O
editor	O
(	O
s	O
)	O
.	O
MDPI	O
and	O
/	O
or	O
the	O
editor	O
(	O
s	O
)	O
disclaim	O
responsibility	O
for	O
any	O
injury	O
to	O
people	O
or	O
property	O
resulting	O
from	O
any	O
ideas	O
,	O
methods	O
,	O
instructions	O
or	O
products	O
referred	O
to	O
in	O
the	O
content	O
.	O
The	O
following	O
supporting	O
information	O
can	O
be	O
downloaded	O
at	O
:	O
https	O
:	O
/	O
/	O
www	O
.	O
mdpi	O
.	O
com	O
/	O
article	O
/	O
10	O
.	O
3390	O
/	O
foods12051092	O
/	O
s1	O
,	O
Figure	O
S1	O
.	O
Filtering	O
and	O
denoising	O
Amplicon	O
Sequence	O
Variants	O
(	O
ASVs	O
)	O
sta	O
-	O
tistics	O
following	O
the	O
DADA2	O
pipeline	O
;	O
Figure	O
S2	O
.	O
Boxplots	O
of	O
the	O
weighted	O
(	O
A	O
)	O
and	O
unweighted	O
(	O
B	O
)	O
UniFrac	O
distances	O
to	O
G1	O
are	O
shown	O
;	O
Figure	O
S3	O
.	O
Canonical	O
correspondence	O
analysis	O
(	O
CCA	O
)	O
among	O
groups	O
treated	O
with	O
ceftriaxone	O
;	O
Figure	O
S4	O
.	O
Canonical	O
correspondence	O
analysis	O
(	O
CCA	O
)	O
among	O
groups	O
treated	O
with	O
LG	O
-	O
G12	O
and	O
ceftriaxone	O
;	O
Figure	O
S5	O
.	O

Box	O
plot	O
showing	O
the	O
distribution	O
in	O
the	O
proportion	O
of	O
selected	O
MetaCyc	O
pathways	O
between	O
the	O
groups	O
G5	O
and	O
G9	O
;	O
Table	O
S1	O
.	O
Pairwise	O
com	O
-	O
parison	O
(	O
G7	O
vs	O
.	O
G3	O
)	O
of	O
PICRUSt2	O
predicted	O
pathway	O
abundances	O
;	O
Table	O
S2	O
.	O
Pairwise	O
comparison	O
(	O
G9	O
vs	O
.	O
G5	O
)	O
of	O
PICRUSt2	O
predicted	O
pathway	O
abundances	O
;	O
Table	O
S3	O
.	O
Pairwise	O
comparison	O
(	O
G8	O
vs	O
.	O
G4	O
)	O
of	O
PICRUSt2	O
predicted	O
pathway	O
abundances	O
.	O
Conceptualization	O
,	O
M	O
.	O
d	O
.	O
M	O
.	O
e	O
.	O
D	O
.	O
;	O
methodology	O
,	O
M	O
.	O
d	O
.	O
M	O
.	O
e	O
.	O
D	O
.	O
,	O
S	O
.	O
A	O
.	O
d	O
.	O
R	O
.	O
L	O
.	O
and	O
L	O
.	O
L	O
.	O
d	O
.	O
C	O
.	O
;	O
software	O
,	O
V	O
.	O
d	O
.	O
S	O
.	O
D	O
.	O
,	O
L	O
.	O
F	O
.	O
M	O
.	O
M	O
.	O
and	O
D	O
.	O
P	O
.	O
;	O
formal	O
analysis	O
,	O
M	O
.	O
d	O
.	O
M	O
.	O
e	O
.	O
D	O
.	O
,	O
V	O
.	O
d	O
.	O
S	O
.	O
D	O
.	O
,	O
L	O
.	O
F	O
.	O
M	O
.	O
M	O
.	O
,	O
D	O
.	O
P	O
.	O
,	O
S	O
.	O
A	O
.	O
d	O
.	O
R	O
.	O
L	O
.	O
and	O
L	O
.	O
L	O
.	O
d	O
.	O
C	O
.	O
;	O
resources	O
,	O
H	O
.	O
C	O
.	O
M	O
.	O
,	O
L	O
.	O
L	O
.	O
d	O
.	O
C	O
.	O
,	O
T	O
.	O
A	O
.	O
d	O
.	O
O	O
.	O
M	O
.	O
,	O
S	O
.	O
S	O
.	O
P	O
.	O
,	O
L	O
.	O
L	O
.	O
O	O
.	O
and	O
M	O
.	O
d	O
.	O
C	O
.	O
G	O
.	O
P	O
.	O
;	O
data	O
curation	O
,	O
V	O
.	O
d	O
.	O
S	O
.	O
D	O
.	O
,	O
L	O
.	O
F	O
.	O
M	O
.	O
M	O
.	O
and	O
D	O
.	O
P	O
.	O
;	O
visualization	O
,	O
M	O
.	O
d	O
.	O
M	O
.	O
e	O
.	O
D	O
.	O
and	O
G	O
.	O
d	O
.	O
C	O
.	O
Á	O
.	O
A	O
.	O
;	O
writing	O
—	O
original	O
draft	O
preparation	O
,	O
M	O
.	O
d	O
.	O
M	O
.	O
e	O
.	O
D	O
.	O
;	O
V	O
.	O
d	O
.	O
S	O
.	O
D	O
.	O
;	O
and	O
G	O
.	O
d	O
.	O
C	O
.	O
Á	O
.	O
A	O
.	O
writing	O
—	O
review	O
and	O
editing	O
.	O
G	O
.	O
d	O
.	O
C	O
.	O
Á	O
.	O
A	O
.	O
and	O
M	O
.	O
d	O
.	O
C	O
.	O
G	O
.	O
P	O
.	O
;	O
supervision	O
,	O
T	O
.	O
A	O
.	O
d	O
.	O
O	O
.	O
M	O
.	O
and	O
M	O
.	O
d	O
.	O
C	O
.	O
G	O
.	O
P	O
.	O
All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O
The	O
Animal	O
Ethics	O
Committee	O
of	O
Universidade	O
Federal	O
de	O
Viçosa	O
approved	O
the	O
exper	O
-	O
iment	O
according	O
to	O
the	O
protocols	O
numbers	O
09	O
/	O
2017	O
and	O
33	O
/	O
2018	O
,	O
and	O
the	O
principles	O
es	O
-	O
tablished	O
by	O
the	O
National	O
Animal	B-methodology
Experimentation	I-methodology
Control	O
Council	O
.	O

Not	O
applicable	O
.	O
The	O
data	O
presented	O
in	O
this	O
study	O
are	O
available	O
on	O
request	O
from	O
the	O
corresponding	O
author	O
.	O
The	O
data	O
are	O
not	O
publicly	O
available	O
due	O
to	O
privacy	O
restrictions	O
.	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
